--- title: "Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/295709781.md" description: "Travere Therapeutics announced inducement equity grants to 12 new employees under Nasdaq Listing Rule 5635(c)(4). On August 10, 2026, the Compensation Committee granted restricted stock units (RSUs) covering 38,940 shares of common stock. These RSUs vest over four years, with 25% vesting annually, contingent on continued employment." datetime: "2026-08-12T13:00:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295709781.md) - [en](https://longbridge.com/en/news/295709781.md) - [zh-HK](https://longbridge.com/zh-HK/news/295709781.md) generator: "portal-rs" --- # Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google Add on Google SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on August 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 12 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 38,940 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with 25% of the shares vesting on each anniversary of the grant date, subject to the new employee’s continued service relationship with Travere through the applicable vesting dates. **About Travere Therapeutics** At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260812597154/en/ Media: 888-969-7879 mediarelations@travere.com Investors: 888-969-7879 IR@travere.com Source: Travere Therapeutics, Inc. ### Related Stocks - [TVTX.US](https://longbridge.com/en/quote/TVTX.US.md) ## Related News & Research - [Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Recommendation of "Moderate Buy" by Analysts](https://longbridge.com/en/news/296673080.md) - [97,573 Shares in Travere Therapeutics, Inc. $TVTX Acquired by Rice Hall James & Associates LLC](https://longbridge.com/en/news/296209446.md) - [Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News](https://longbridge.com/en/news/296654527.md) - [Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | ZVRA Stock News](https://longbridge.com/en/news/296652469.md) - [Corbus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | CRBP Stock News](https://longbridge.com/en/news/296118418.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**